Viral Hepatitis

This webinar discusses common myths about hepatitis B prevention and transmission and how to address common misconceptions.

The National Viral Hepatitis Progress Report provides information on seven data indicators, providing an objective way to assess progress toward achieving key viral hepatitis goals.

This webinar explores strategies for HCV testing and linkage to care for people currently in or transitioning from prison.

This article provides a comprehensive overview of rashes associated with hepatitis C (HCV), emphasizing their appearance, causes, and the importance of medical evaluation. While HCV primarily affects the liver, chronic infection can manifest dermatologically in up to one-third of patients. The article categorizes HCV-related rashes into hives, lichen planus, macules, and purpura, describing their typical color, shape, and distribution.

This article provides a comprehensive overview of Doxycycline Post-Exposure Prophylaxis (Doxy-PEP), an antibiotic used to reduce the risk of bacterial sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis following condomless sex. It explains how Doxy-PEP works, the correct dosage and timing (200 mg within 24–72 hours after exposure), and who should or should not take it, including guidance for pregnant individuals. The article discusses potential side effects, interactions with other medications, and considerations regarding antibiotic resistance.

This article provides a comprehensive overview of hepatitis B (HBV) and its relationship to liver cancer and other potential health risks. Hepatitis B is a viral infection transmitted through infected blood and bodily fluids, which can lead to liver inflammation, fibrosis, cirrhosis, and ultimately liver cancer. The article emphasizes that HBV can be asymptomatic, making screening critical for early detection and prevention.

This fact sheet discusses how research from the University of California San Diego and published in Clinical Infectious Diseases, estimates the hepatitis A vaccination coverage needed to prevent outbreaks among people who inject drugs (PWID). Analyzing surveillance data from 16 states with recent hepatitis A outbreaks linked to PWID, the study found that vaccination coverage of at least 80% may be necessary to reliably achieve herd immunity—though some states, such as West Virginia, may require higher levels.

This webinar recording discusses how the hepatitis A landscape is changing globally. Between 2010 and 2019, the number of deaths from hepatitis A decreased globally by 10%, despite the number of cases increasing by 4%. A number of factors have helped drive these changes, including globalization and increased hepatitis A vaccination rates.